Figure 5
Validation of the DTBP-based AD syringe filter system using LNCap and HepG2 cells. (A–C) The capacity of the DTBP-based AD in filter system was evaluated with the LNCap cancer cell line, in the range of 10–106 cells. The DNA extracted using the DTBP-based AD in filter system was analyzed by (A) PCR for β-actin and TGF-β. The proteins isolated by the DTBP-based AD in filter system were assessed by (B) Western blot for β-actin and (C) silver staining. (D–F) The capacity of the DTBP-based AD in filter system was evaluated with the HepG2 cancer cell line, in the range of 10–106 cells. The DNA extracted using the DTBP-based AD in filter system was analyzed by (D) PCR for β-actin and TGF-β. The proteins isolated by the DTBP-based AD in filter system were assessed by (E) Western blot for β-actin, TAB1, and (F) silver staining. (DE: diatomaceous earth, AD: APDMS-functionalized DE, M: size marker, N: negative control).
